#Sweden #Stockholm #Drug Discovery #Salipro Biotech #Salipro® platform

Salipro Biotech Strengthens International IP Portfolio

Salipro Biotech AB, a leading Swedish biotechnology firm, has recently received granted patents in Australia and Singapore, marking a pivotal moment in its international intellectual property strategy. This expansion underscores the firm’s commitment to advancing drug discovery for challenging pharmaceutical targets.

Overview of the Salipro® Platform

The Salipro® platform is a proprietary technology uniquely designed to isolate and purify native membrane proteins that play a vital role in various therapeutic drugs. The significance of these proteins lies in their involvement with numerous drug targets, including G protein-coupled receptors (GPCRs), ion channels, and transporters—areas that have traditionally posed challenges in drug development.

By leveraging the Salipro® technology, Salipro Biotech enables the launch of innovative drug discovery initiatives, covering antibody discovery, small molecule drug screening, and structure-based drug design.

Importance of the Newly Granted Patents

The new patents, titled "Production of Salipro® Particles" (Australian Patent No. 2020257991; Singaporean Patent No. 11202111111U), elaborate on key processes associated with the Salipro® platform. Jens Frauenfeld, the CEO of Salipro Biotech, highlighted that securing these patents is a transformative step in their strategy to build a formidable patent portfolio that safeguards their unique technological advancements.

Frauenfeld emphasized the crucial role that these patents play in enhancing Salipro's business prospects and long-term growth in strategically important regions. With established patents already granted across major jurisdictions, including the United States, Europe, China, and Japan, the company is keen to solidify its position in the global biotech arena.

Strategic Collaborations and Future Goals

Salipro Biotech aims to forge collaborations and licensing agreements with top pharmaceutical entities as a core part of their strategy. These new patents enrich the company’s value proposition for potential partners, paving the way for groundbreaking advancements in treating previously inaccessible drug targets.

Peter Jahnmatz, the Business Development Director at Salipro Biotech, expressed confidence that these patent grants will not only bolster their development efforts but also enhance their partnerships with leading pharmaceutical firms as they work towards producing next-generation therapeutics.

About Salipro Biotech

Salipro Biotech AB specializes in addressing complex drug targets integral to developing next-generation therapeutics. Headquartered in Stockholm, Sweden, the company maintains a robust IP portfolio dedicated to the Salipro® platform. This unique platform stabilizes membrane proteins in their native forms, allowing them to be utilized in various drug discovery programs, including research on therapeutic antibodies and small molecule drugs.

The company has successfully established multiple research collaborations with prominent pharma and biotech companies to expedite the drug discovery process. With a strong commitment to innovation, Salipro Biotech continues to advance treatments that meet significant unmet medical needs globally.

For further inquiries, you can reach out to Salipro Biotech directly through their website: Salipro Biotech.